Felix Sahm
YOU?
Author Swipe
View article: Employing nanopore sequencing on FFPE-derived DNA for CNS tumor diagnostics
Employing nanopore sequencing on FFPE-derived DNA for CNS tumor diagnostics Open
View article: PTHP-18. Comparison of therapeutic approaches and multimodal molecular profiling in diffuse leptomeningeal glioneural tumor (DLGNT): Results from a European multicenter cohort
PTHP-18. Comparison of therapeutic approaches and multimodal molecular profiling in diffuse leptomeningeal glioneural tumor (DLGNT): Results from a European multicenter cohort Open
Diffuse leptomeningeal glioneural tumor (DLGNT) is a rare primary CNS tumor with a median age at diagnosis of 5 years. In 2016, the WHO Classification of Tumors of the Central Nervous System first recognized DLGNT as a distinct entity. The…
View article: PATH-75. Hetairos enables AI-based histopathological classification of CNS tumours
PATH-75. Hetairos enables AI-based histopathological classification of CNS tumours Open
Central nervous system (CNS) tumours encompass a diverse group of neoplasms with complex histological and molecular profiles. DNA methylation profiling has revolutionised their classification, enabling diagnosis at granular resolution. How…
View article: PATH-60. Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
PATH-60. Advancing CNS tumor diagnostics with expanded DNA methylation-based classification Open
DNA methylation-based classification is integral to contemporary neuro-oncological diagnostics, as highlighted by the current World Health Organization (WHO) classification of central nervous system (CNS) tumors. We introduce the Heidelber…
View article: BIOM-08. CHROMOSOME 1P LOSS AND 1Q GAIN ARE HIGHLY PROGNOSTIC AND CAN INFORM WHO GRADING OF MENINGIOMA
BIOM-08. CHROMOSOME 1P LOSS AND 1Q GAIN ARE HIGHLY PROGNOSTIC AND CAN INFORM WHO GRADING OF MENINGIOMA Open
The CNS WHO grade of meningioma was updated in 2021 to include rare molecular features, namely homozygous deletions of CDKN2A or CDKN2B and TERT promotor mutations. Previous work including the cIMPACT-NOW update 8 have discussed the potent…
View article: IMG-82. Positron emission tomography (PET) use among European Organisation for Research and Treatment of Cancer – Brain Tumour Group (EORTC-BTG) sites – a cross-sectional survey
IMG-82. Positron emission tomography (PET) use among European Organisation for Research and Treatment of Cancer – Brain Tumour Group (EORTC-BTG) sites – a cross-sectional survey Open
BACKGROUND Positron emission tomography (PET) is increasingly used in patients with brain tumors, yet its adoption varies across institutions. METHODS To assess the current landscape, a cross-sectional survey was conducted among European O…
View article: Integrated transcriptomic landscape of medulloblastoma and ependymoma reveals novel tumor subtype-specific biology
Integrated transcriptomic landscape of medulloblastoma and ependymoma reveals novel tumor subtype-specific biology Open
Background Medulloblastoma and ependymoma are common pediatric central nervous system tumors with significant molecular and clinical heterogeneity. While molecular subgrouping has enabled classification into molecular subtypes, the extent …
View article: High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma
High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma Open
Chromosome 8 (chr8) gains are common in cancer, but their contribution to tumor heterogeneity is largely unexplored. Ewing sarcoma (EwS) is defined by FET::ETS fusions with few other recurrent mutations to explain clinical diversity. In Ew…
View article: Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORM
Molecular characterization and clinical features of diffuse midline glioma in the pediatric precision oncology registry INFORM Open
Diffuse midline glioma (DMG; a subtype of pediatric high-grade glioma) is a fatal disease in children, due to the localization in critical structures of the central nervous system, its invasive nature, and limited treatment options. Molecu…
View article: Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas
Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas Open
View article: Tumor-associated macrophages in meningiomas: a novel biomarker for poor survival outperforming the benefits of T cells
Tumor-associated macrophages in meningiomas: a novel biomarker for poor survival outperforming the benefits of T cells Open
View article: Spatial Transcriptomics Characterisation of Radionecrotic Changes in Glioblastoma Patients
Spatial Transcriptomics Characterisation of Radionecrotic Changes in Glioblastoma Patients Open
Background: IDH-wildtype Glioblastoma (GB) is the most prevalent primary CNS tumour in adults. The standard treatment involves radiotherapy, which can cause radionecrotic changes. Progressive GB and radionecrotic changes can be challenging…
View article: JS09.6.A ADVANCING THE MINIMALLY INVASIVE CNS-TUMOR CLASSIFICATION: A COMPARATIVE STUDY OF LIQUID BIOPSY APPROACHES USING NANOPORE SEQUENCING AND PANEL-BASED NGS OF CEREBROSPINAL FLUID CTDNA
JS09.6.A ADVANCING THE MINIMALLY INVASIVE CNS-TUMOR CLASSIFICATION: A COMPARATIVE STUDY OF LIQUID BIOPSY APPROACHES USING NANOPORE SEQUENCING AND PANEL-BASED NGS OF CEREBROSPINAL FLUID CTDNA Open
BACKGROUND Cerebrospinal fluid (CSF) liquid biopsy (LB) enables minimally invasive molecular profiling of central nervous system (CNS) tumors. We compared targeted next-generation sequencing (NGS) and whole-genome Oxford Nanopore sequencin…
View article: KS02.6.A COMPUTATIONAL HISTOPATHOLOGY ENABLES SCALABLE DEEP LEARNING-DRIVEN CNS TUMOR CLASSIFICATION FOR REAL-TIME INTRAOPERATIVE DIAGNOSTICS
KS02.6.A COMPUTATIONAL HISTOPATHOLOGY ENABLES SCALABLE DEEP LEARNING-DRIVEN CNS TUMOR CLASSIFICATION FOR REAL-TIME INTRAOPERATIVE DIAGNOSTICS Open
BACKGROUND Accurate intraoperative diagnosis of central nervous system (CNS) tumors is critical for guiding neurosurgical decision-making. However, the global shortage of trained neuropathologists and limited access to molecular diagnostic…
View article: P04.05.B DEEP LEARNING ANALYSIS OF SPATIALLY RESOLVED SINGLE-CELL TRANSCRIPTOMICS UNCOVERS CELLULAR REORGANIZATION IN GLIOBLASTOMA AT RECURRENCE
P04.05.B DEEP LEARNING ANALYSIS OF SPATIALLY RESOLVED SINGLE-CELL TRANSCRIPTOMICS UNCOVERS CELLULAR REORGANIZATION IN GLIOBLASTOMA AT RECURRENCE Open
BACKGROUND Recent studies using single-cell RNA sequencing (scRNA-seq) have provided insights into the cellular composition and molecular states in glioblastoma (GBM). However, these studies have not identified significant differences betw…
View article: P03.22.A USE OF POSITRON EMISSION TOMOGRAPHY (PET) IN PATIENTS WITH BRAIN TUMOURS AMONG EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - BRAIN TUMOUR GROUP (EORTC-BTG) SITES
P03.22.A USE OF POSITRON EMISSION TOMOGRAPHY (PET) IN PATIENTS WITH BRAIN TUMOURS AMONG EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER - BRAIN TUMOUR GROUP (EORTC-BTG) SITES Open
BACKGROUND Data on the use of positron emission tomography (PET) among neuro-oncology centers in Europe are scarce. MATERIAL AND METHODS From 06/2024 to 08/2024, a cross-sectional survey among European Organization for Research and Treatme…
View article: OS13.5.A INTEGRATIVE MULTIOMICS ANALYSIS IDENTIFIES TUMOR-ASSOCIATED MACROPHAGES AS NOVEL INDEPENDENT BIOMARKER FOR POOR SURVIVAL IN MENINGIOMAS
OS13.5.A INTEGRATIVE MULTIOMICS ANALYSIS IDENTIFIES TUMOR-ASSOCIATED MACROPHAGES AS NOVEL INDEPENDENT BIOMARKER FOR POOR SURVIVAL IN MENINGIOMAS Open
BACKGROUND Tumor-associated macrophages (TAMs) represent the main immune cell population in various brain malignancies, but their role in the meningioma (MGM) microenvironment remains to be elucidated. MATERIAL AND METHODS Here, we investi…
View article: P17.06.A VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
P17.06.A VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR) Open
BACKGROUND The international randomized placebo-controlled phase III INDIGO trial has shown improved progression free survival (PFS) of the isocitrate dehydrogenase (IDH) inhibitor vorasidenib in IDH-mutant diffuse gliomas that were consid…
View article: P05.10.B LIQUID BIOPSY VS. STEREOTACTIC BIOPSY IN NON-RESECTABLE GLIOMAS: A MINIMALLY INVASIVE ALTERNATIVE WITH CLINICAL IMPACT?
P05.10.B LIQUID BIOPSY VS. STEREOTACTIC BIOPSY IN NON-RESECTABLE GLIOMAS: A MINIMALLY INVASIVE ALTERNATIVE WITH CLINICAL IMPACT? Open
BACKGROUND Stereotactic biopsies (STX) are essential for brain tumor diagnosis but carry significant risks, including permanent morbidity (3.1-6.4%) and mortality (0-1.7%)¹ with even higher complication rates for tumors in brainstem, thala…
View article: P04.13.B SPATIAL HETEROGENEITY OF CAR-T ANTIGEN EXPRESSION IN GLIOBLASTOMA
P04.13.B SPATIAL HETEROGENEITY OF CAR-T ANTIGEN EXPRESSION IN GLIOBLASTOMA Open
BACKGROUND Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough immunotherapy for multiple cancers, yet its efficacy remains limited in glioblastoma due to tumor heterogeneity, immune-evasion of the microenvironme…
View article: OS12.4.A AI-BASED HISTOPATHOLOGICAL CLASSIFICATION OF CENTRAL NERVOUS SYSTEM TUMOURS
OS12.4.A AI-BASED HISTOPATHOLOGICAL CLASSIFICATION OF CENTRAL NERVOUS SYSTEM TUMOURS Open
BACKGROUND DNA methylation profiling is central to CNS tumour diagnostics, providing molecular classification beyond conventional histopathology. However, its use is constrained by extended turnaround time, high costs and the need for spec…
View article: KS03.6.A THE RECURRENT TISSUE STATES ACROSS ADULT GLIOMAS AS REVEALED BY SPATIAL TRANSCRIPTOMICS
KS03.6.A THE RECURRENT TISSUE STATES ACROSS ADULT GLIOMAS AS REVEALED BY SPATIAL TRANSCRIPTOMICS Open
BACKGROUND Adult gliomas are a diverse class of tumors with substantial molecular and pathological variation. While prior single-cell omics studies have characterized intratumoral heterogeneity, they often examined tumors in isolation, thu…
View article: P14.10.A DISTINCT EPIGENETIC AND TRANSCRIPTIONAL PROFILES OF EPSTEIN-BARR VIRUS (EBV) POSITIVE AND NEGATIVE PRIMARY CNS LYMPHOMAS
P14.10.A DISTINCT EPIGENETIC AND TRANSCRIPTIONAL PROFILES OF EPSTEIN-BARR VIRUS (EBV) POSITIVE AND NEGATIVE PRIMARY CNS LYMPHOMAS Open
BACKGROUND Epstein-Barr virus (EBV)+ and EBV- primary CNS lymphomas (PCNSL) carry distinct mutational landscapes, but their transcriptional and epigenetic profiles have not been integrated and compared. This precludes further insights into…
View article: P07.16.B A NOVEL METHOD ENABLING THE DETECTION OF INTRACELLULAR DRUGS BY SEQUENCING ON SINGLE-CELL LEVEL IN GLIOBLASTOMA
P07.16.B A NOVEL METHOD ENABLING THE DETECTION OF INTRACELLULAR DRUGS BY SEQUENCING ON SINGLE-CELL LEVEL IN GLIOBLASTOMA Open
BACKGROUND Glioblastoma is an aggressive and incurable primary brain tumor, primarily due to its resistance to standard therapies and imminent recurrence. The increasing importance of Single-Cell RNA Sequencing (scRNA-Seq) in deciphering t…
View article: P14.08.A GLIOSARCOMA SPATIAL ARCHITECTURE IS DEFINED BY UNIQUE ECM AND IMMUNE REMODELING TRANSCRIPTIONAL PROFILES
P14.08.A GLIOSARCOMA SPATIAL ARCHITECTURE IS DEFINED BY UNIQUE ECM AND IMMUNE REMODELING TRANSCRIPTIONAL PROFILES Open
BACKGROUND Gliosarcoma (GS) is a rare, aggressive variant of Glioblastoma (GB), representing approximately 2% of all GB cases. It is characterized by its biphasic histological growth pattern with glial and sarcomatous areas. Little is know…
View article: P13.20.A SPATIAL HETEROGENEITY OF METHYLATION CLASSES IN MENINGIOMAS: IMPACT ON CLASSIFICATION ACCURACY AND CLINICAL PROGNOSIS
P13.20.A SPATIAL HETEROGENEITY OF METHYLATION CLASSES IN MENINGIOMAS: IMPACT ON CLASSIFICATION ACCURACY AND CLINICAL PROGNOSIS Open
BACKGROUND Meningiomas are the most frequent primary central nervous system tumors and are predominantly benign. Although the risk of tumor recurrence generally correlates with malignancy, some patients with histologically benign meningiom…
View article: OS13.6.A A SINGLE-CELL AND SPATIAL ATLAS OF MENINGIOMA HETEROGENEITY ACROSS TUMOR CLASSES
OS13.6.A A SINGLE-CELL AND SPATIAL ATLAS OF MENINGIOMA HETEROGENEITY ACROSS TUMOR CLASSES Open
BACKGROUND Most meningiomas are benign, slow-growing tumors. However, CNS WHO grades 2 and 3 meningiomas display significantly higher aggressiveness and poorer prognosis. Recent investigations into the molecular biology of meningiomas have…
View article: P08.16.B UTILIZATION OF UNIVERSAL-TARGETING MSA2 CAR-T CELLS FOR THE TREATMENT OF GLIOBLASTOMA
P08.16.B UTILIZATION OF UNIVERSAL-TARGETING MSA2 CAR-T CELLS FOR THE TREATMENT OF GLIOBLASTOMA Open
BACKGROUND Glioblastoma (GB) remains refractory to chimeric antigen receptor (CAR)-T cell therapy, mainly attributed to tumor heterogeneity and antigen escape. CAR-T cells utilizing monomeric streptavidin-2 (mSA2) instead of a traditional …
View article: Expansion of the spectrum of tumors diagnosed as myxopapillary ependymomas
Expansion of the spectrum of tumors diagnosed as myxopapillary ependymomas Open
View article: Adult pilocytic astrocytomas: challenging the benign paradigm with surgical risks, recurrence dynamics, and molecular insights
Adult pilocytic astrocytomas: challenging the benign paradigm with surgical risks, recurrence dynamics, and molecular insights Open
Purpose Adult pilocytic astrocytoma (APA) is rare and clinically distinct from pediatric counterparts. Despite generally favorable prognosis, recurrence rates vary significantly based on tumor characteristics and surgical approaches. Liter…